nimotuzumab + gemcitabine + capecitabine

nimotuzumab + gemcitabine + capecitabine is a combination therapy regimen being evaluated as a postoperative adjuvant treatment for resected pancreatic ductal adenocarcinoma. The regimen consists of nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), combined with the chemotherapy doublet GX, which comprises gemcitabine and capecitabine. Nimotuzumab works by binding to EGFR, thereby inhibiting tumor cell proliferation, inducing apoptosis, and reducing angiogenesis. Gemcitabine is a nucleoside analog that interferes with DNA synthesis, while capecitabine is an oral fluoropyrimidine carbamate that is converted to 5-fluorouracil within the body, acting as an antimetabolite. This combination is primarily being developed and studied by the Tianjin Medical University Cancer Institute and Hospital to improve disease-free and overall survival in patients following surgical resection of pancreatic tumors.

Brand names

TheraCIMCIMAherGemzarXeloda

Other names

Nimotuzumab + GXNimotuzumab + Gemcitabine + Capecitabine